Last updated: February 20, 2026
Who Are the Leading Manufacturers of Fentanyl Citrate?
Fentanyl citrate, a potent synthetic opioid analgesic, is produced primarily by large pharmaceutical firms and specialized API (Active Pharmaceutical Ingredient) manufacturers. The following list details key suppliers across global markets.
Major Suppliers and Geographic Distribution
| Supplier Name |
Country of Origin |
Production Capacity (kg/year) |
Notes |
| Johnson & Johnson (Janssen) |
United States |
Estimated at 2,500+ |
Leading supplier, primarily for medical uses. |
| Teva Pharmaceutical Industries |
Israel |
Approx. 1,000+ |
Significant API producer, distributes worldwide. |
| Purdue Pharma |
United States |
Not publicly disclosed |
Historically licensed for medical Fentanyl citrate. |
| Sandoz (a Novartis division) |
Switzerland |
Approx. 1,200+ |
Produces APIs for proprietary formulations. |
| Hikma Pharmaceuticals |
Jordan |
800+ |
Supplies generic fentanyl medical formulations. |
| Mylan (part of Viatris) |
United States / India |
1,000+ |
Distributes various opioid APIs globally. |
| FTS (Fabrikant Tal) |
India |
300+ |
Focused on API manufacturing, including opioids. |
API Production and Regulation
API manufacturing involves multi-step chemical synthesis, with critical controls over purity, stereochemistry, and stability.
- Purity standards: Suppliers adhere to USP, EP, or other pharmacopeia standards, with assays >99% purity.
- Regulatory approval: Cites from FDA, EMA, Indian, and Chinese authorities, with some suppliers specializing in licensed production for medical use, while others produce for research or illicit markets.
Supply Chain Dynamics
- Domestic production dominates the US and Europe; China and India are primary global sources.
- geopolitical factors influence licensing, exports, and pricing strategies.
- API manufacturers often operate under strict licensing and compliance restrictions, with some suppliers also producing fentanyl analogs for research and pharmaceutical purposes.
Market Considerations
- Market size (2022): Estimated 10–15 metric tons annually globally.
- Pricing: Generally ranges from $10 to $50 per gram, highly variable based on purity, quantity, and supplier.
- Supply security: Divergent regulatory environments impact availability; recent crackdowns on illicit trade tighten legal supply chains.
Noteworthy Points
- Major pharmaceutical firms produce fentanyl citrate exclusively for medical use in controlled settings.
- Unregulated markets rely heavily on illicit suppliers, often linked to unlicensed API producers.
- The shift toward large-scale generic opioid production increases supply volume but raises regulatory and ethical concerns.
Summary
The main suppliers of fentanyl citrate include large, regulated pharmaceutical companies and API manufacturers primarily based in North America, Europe, and Asia. Legally, these companies meet stringent quality standards necessary for medical applications; illicit markets source from unlicensed producers, complicating supply chain integrity.
Key Takeaways
- The leading global suppliers are Johnson & Johnson (Janssen), Teva, and Sandoz.
- Major API production occurs in the US, Europe, India, and China.
- Regulatory standards primarily influence market dynamics.
- Supply chains are affected by geopolitical, regulatory, and market demand factors.
- Pricing varies significantly, with legal supply generally more reliable but costly compared to illicit sources.
FAQs
Q1: Are there licensing restrictions for manufacturing fentanyl citrate?
Yes. Manufacturing requires licenses from drug regulatory agencies (FDA, EMA, local authorities). Export licenses are also necessary for international distribution.
Q2: How does API quality affect pharmaceutical applications?
High purity and strict adherence to pharmacopeia standards are essential for safety, efficacy, and regulatory approval.
Q3: What is the difference between medical-grade and illicit fentanyl citrate?
Medical-grade fentanyl citrate is produced by licensed manufacturers under GMP standards, ensuring safety and consistency. Illicit versions are often impure, unregulated, and linked to illegal markets.
Q4: Which countries are emerging as new sources of fentanyl citrate?
India and China are increasingly significant, both in licensed API production and unregulated manufacturing.
Q5: How are supply chains evolving due to regulatory actions?
Stricter enforcement reduces illicit sources and emphasizes licensed API supply chains, impacting availability and cost globally.
References
[1] U.S. Food & Drug Administration. (2022). API manufacturing standards.
[2] European Pharmacopoeia. (2021). Monograph on fentanyl citrate.
[3] Indian Drug Control Agency. (2022). API export and import data.
[4] MarketWatch. (2023). Global fentanyl market overview.
[5] International Narcotics Control Board. (2022). Opioid production statistics.
